Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

1.

Anti-interleukin-6 receptor antibody therapy-induced retinopathy in a patient with rheumatoid arthritis.

Tada A, Hashida N, Tanaka T, Nishida K.

Case Rep Rheumatol. 2012;2012:270315. doi: 10.1155/2012/270315. Epub 2012 Dec 24.

PMID:
23424706
[PubMed]
Free PMC Article
2.

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.

Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T.

Blood. 2008 Nov 15;112(10):3959-64. doi: 10.1182/blood-2008-05-155846. Epub 2008 Sep 10.

PMID:
18784373
[PubMed - indexed for MEDLINE]
Free Article
3.

Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis.

Hushaw LL, Sawaqed R, Sweis G, Reigle J, Gopal A, Brandt D, Sweis N, Curran J, Niewold TB, Sweiss NJ.

Ther Clin Risk Manag. 2010 Apr 15;6:143-52.

PMID:
20421913
[PubMed]
Free PMC Article
4.

Tocilizumab for the treatment of rheumatoid arthritis.

Tanaka T, Ogata A, Narazaki M.

Expert Rev Clin Immunol. 2010 Nov;6(6):843-54. doi: 10.1586/eci.10.70. Review.

PMID:
20979549
[PubMed - indexed for MEDLINE]
5.

Acute anterior uveitis after discontinuation of tocilizumab in a patient with rheumatoid arthritis.

Sato T, Minakuchi S, Mochizuki M, Takeuchi M.

Clin Ophthalmol. 2014 Jan 8;8:187-90. doi: 10.2147/OPTH.S54929. eCollection 2014.

PMID:
24531503
[PubMed]
Free PMC Article
6.

Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases.

Ding C, Jones G.

Rev Recent Clin Trials. 2006 Sep;1(3):193-200. Review.

PMID:
18473972
[PubMed - indexed for MEDLINE]
7.

The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody.

Mihara M, Nishimoto N, Ohsugi Y.

Expert Opin Biol Ther. 2005 May;5(5):683-90. Review.

PMID:
15934843
[PubMed - indexed for MEDLINE]
8.

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.

Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, Kishimoto T.

Mod Rheumatol. 2009;19(1):12-9. doi: 10.1007/s10165-008-0125-1. Epub 2008 Nov 1.

PMID:
18979150
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

[Humanized anti-human IL-6 receptor antibody, tocilizumab].

Nishimoto N.

Nihon Rinsho. 2007 Jul;65(7):1218-25. Review. Japanese.

PMID:
17642235
[PubMed - indexed for MEDLINE]
10.

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T; CHARISMA Study Group.

Arthritis Rheum. 2006 Sep;54(9):2817-29. Erratum in: Arthritis Rheum. 2008 Mar;58(3):887.

PMID:
16947782
[PubMed - indexed for MEDLINE]
Free Article
11.

Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy.

Snir A, Kessel A, Haj T, Rosner I, Slobodin G, Toubi E.

Clin Exp Rheumatol. 2011 Jul-Aug;29(4):697-700. Epub 2011 Sep 1.

PMID:
21813064
[PubMed - indexed for MEDLINE]
12.

Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.

Nakahara H, Nishimoto N.

Endocr Metab Immune Disord Drug Targets. 2006 Dec;6(4):373-81. Review.

PMID:
17214583
[PubMed - indexed for MEDLINE]
13.

[Clinical benefits of anti-human IL-6 receptor antibody therapy].

Nishimoto N.

Clin Calcium. 2007 Apr;17(4):562-8. Review. Japanese.

PMID:
17404486
[PubMed - indexed for MEDLINE]
14.

Clinical value of blocking IL-6 receptor.

Mima T, Nishimoto N.

Curr Opin Rheumatol. 2009 May;21(3):224-30. doi: 10.1097/BOR.0b013e3283295fec. Review.

PMID:
19365268
[PubMed - indexed for MEDLINE]
15.

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.

Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ.

Arthritis Rheum. 2008 Oct;58(10):2968-80. doi: 10.1002/art.23940.

PMID:
18821691
[PubMed - indexed for MEDLINE]
Free Article
16.

Humanized antihuman IL-6 receptor antibody, tocilizumab.

Nishimoto N, Kishimoto T.

Handb Exp Pharmacol. 2008;(181):151-60. Review.

PMID:
18071945
[PubMed - indexed for MEDLINE]
17.

Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis.

Zhang X, Peck R.

Expert Rev Clin Pharmacol. 2011 Sep;4(5):539-58. doi: 10.1586/ecp.11.33. Review.

PMID:
22114882
[PubMed - indexed for MEDLINE]
18.

Tocilizumab for the treatment of rheumatoid arthritis.

Mima T, Nishimoto N.

Expert Rev Clin Immunol. 2008 Mar;4(2):165-72. doi: 10.1586/1744666X.4.2.165.

PMID:
20477048
[PubMed]
19.

Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA).

Kobayashi K, Okamoto Y, Inoue H, Usui T, Ihara M, Kawamata J, Miki Y, Mimori T, Tomimoto H, Takahashi R.

Intern Med. 2009;48(15):1307-9. Epub 2009 Aug 3.

PMID:
19652436
[PubMed - indexed for MEDLINE]
Free Article
20.

Refractory uveitis in patient with castleman disease successfully treated with tocilizumab.

Oshitari T, Kajita F, Tobe A, Itami M, Yotsukura J, Baba T, Yamamoto S.

Case Rep Ophthalmol Med. 2012;2012:968180. doi: 10.1155/2012/968180. Epub 2012 Nov 6.

PMID:
23198204
[PubMed]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk